HeLa Hücrelerinde Sisplatinin MTOR, AKT, CCND1 ve STAT3 mRNA İfadesi Üzerine Etkileri

HeLa Hücrelerinde Sisplatinin MTOR, AKT, CCND1 ve STAT3 mRNA İfadesi Üzerine Etkileri

  • Ebru Alp Faculty of Medicine, Giresun University
  • Akın Yılmaz Faculty of Medicine, Hitit University
  • Hacer İlke Önen Faculty of Medicine, Gazi University
  • Ece Konaç Faculty of Medicine, Gazi University
  • Abdullah Ekmekçi Faculty of Medicine, Gazi University
  • Emine Sevda Menevşe Faculty of Medicine, Gazi University
  • Adnan Menevşe Faculty of Medicine, Gazi University

Abstract

Objective: Cervical cancer is one of the most tumors seen in womans and second leading cause of cancer death in women. Cisplatin (CDDP), a platin based compound, is the most important chemotherapeutic agent and effectively used for the treatment of sarcomas and solid tumors. It binds to the DNA with crosslinks and leads inhibition of replication, causing DNA damage. As a result of this action, apoptotic pathways are induced and cell death occurs. Methods: In this study, HeLa cells were treated with different concentrations of CDDP at 24 and 48 hours. Cell viability was determined by XTT method. Moreover, after treatment with selected doses of cisplatin, quantitative mRNA expression of mTOR, AKT, CCND1 and STAT-3 genes was analyzed using Real-Time PCR. Results: IC50 concentration of CDDP was found to be about 60 µM for 24h and 8 µM for 48h treatment. Moreover, all analyzed genes’ expression was shown to diminish only after 24 h treatment. On the other hand, no statistically significant change was found after 48 h cisplatin exposure with respect to quantitative mRNA expression. Conclusion: In our study, different mRNA expression pattern was found after CDDP treatment regarding to exposure time. Our study has been contributed the literature in terms of detecting the effect of conventional chemotherapeutic CDDP on cell survival pathways.

Author Biographies

Ebru Alp, Faculty of Medicine, Giresun University
Department of Medical Biology
Akın Yılmaz, Faculty of Medicine, Hitit University
Department of Medical Biology
Hacer İlke Önen, Faculty of Medicine, Gazi University
Department of Medical Biology and Genetics
Ece Konaç, Faculty of Medicine, Gazi University
Department of Medical Biology and Genetics
Abdullah Ekmekçi, Faculty of Medicine, Gazi University
Department of Medical Biology and Genetics
Emine Sevda Menevşe, Faculty of Medicine, Gazi University
Department of Medical Biology and Genetics
Adnan Menevşe, Faculty of Medicine, Gazi University
Department of Medical Biology and Genetics

References

Siegel RL, Miller KD, Jemal A. Cancer Statistics. CA: A Cancer Journal for Clinicians. 2018;68:7-30.

Sahin K, Tuzcu M, Basak N, et al. Sensitization of Cervical Cancer Cells to Cisplatin by Genistein: The Role of NFκB and Akt/mTOR Signaling Pathways. Journal of Oncology. 2012;2012:461562.

Duenas-Gonzalez, A, Zarba JJ, Patel F, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. Journal of Clinical Oncology. 2011;29:1678-85.

Spitzner M, Ebner R, Wolff HA, et al. STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy. Cancers (Basel). 2014;6:1986-2011.

Xu Y, Yu H, Qin H, et al. Inhibition of autophagy enhances cisplatin cytotoxicity through endoplasmic reticulum stress in human cervical cancer cells. Cancer Letters. 2012; 314:232-43.

Singh M, Bhui K, Singh R, et al. Tea polyphenols enhance cisplatin chemosensitivity in cervical cancer cells via induction of apoptosis. Life Science. 2013;93:7-16.

Florea AM, Büsselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel). 2011;3:1351-71.

Shinomiya N, Shinomiya M, Wakiyama H, et al. Enhancement of CDDP cytotoxicity by caffeine is characterized by apoptotic cell death. Experimental Cell Research. 1994;210: 236-42.

Pil, P, Lippard SJ. Cisplatin and Related Drugs, in: Bertino, J.R. (ed) “Encyclopedia of Cancer, vol. 1. New York, NY: Academic Press, pp. 392-410, 1997

Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005;24:7455 64.

Toker A, Yoeli Lerner M. Akt signaling and cancer: surviving but not moving on. Cancer Research. 2006;66:3963 66.

Zhang J, Zhang LL, Shen L, et al. Regulation of AKT gene expression by cisplatin. Oncology Letters. 2013;5:756-60.

Deng R, Tang J, Xie BF, et al. SYUNZ 16, a newly synthesized alkannin derivative, induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of AKT/FOXO signal pathway. International Journal of Cancer. 2010;127:220 9.

Yao X, Zhu F, Zhao Z, et al. Arctigenin enhances chemosensitivity of cancer cells to cisplatin through inhibition of the STAT3 signaling pathway. Journal of Cellular Biochemistry. 2011;112:2837-49.

Sheng WJ, Jiang H, Wu DL, et al. Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer. Brazilian Journal of Medical and Biological Research. 2013;46:650-8.

Han L, Wu JL, Yang LX. Effect of combination of rapamycin and cisplatin on human cervical carcinoma Hela cells. Contemporary Oncology (Pozn). 2012;16:512-5.

Hou G, Yang S, Zhou Y, et al. Targeted inhibition of mTOR signaling improves sensitivity of esophageal squamous cell carcinoma cells to cisplatin. J Immunology Research. 2014;2014:845763.

P´opulo H, Lopes JM, Soares P. The mTOR signalling pathway in human cancer. International Journal of Molecular Sciences. 2012;13:1886-918.

Ma XM, Blenis J. Molecular mechanisms of mTOR mediated translational control. Nature Reviews Molecular Cell Biology. 2009;10:307-18.

Leisching GR, Loos B, Botha MH, et al. The role of mTOR during cisplatin treatment in an in vitro and ex vivo model of cervical cancer. Toxicology. 2015;335:72-8.

Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Research. 2002;30:e36.

Faried LS, Faried A, Kanuma T, et al. Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy. Molecular Carcinogenesis. 2008;47,446-57.

Gultekin KE, Yurdakonar MK, Yaman E, et al. Effects of cisplatin and panobinostat on human mesothelial(Met-5A) and malignant pleural mesothelioma (MSTO-211H) cells. Genetics and Molecular Research. 2013;12:5405-13.

Onen HI, Yilmaz A, Alp E, et al. EF24 and RAD001 potentiates the anticancer effect of platinum-based agents in human malignant pleural mesothelioma (MSTO-211H) cells and protects nonmalignant mesothelial (MET-5A) cells. Human and Experimental Toxicology. 2015;34:117-26.

Varol N, Konac E, Onen IH, et al. The epigenetically regulated effects of Wnt antagonists on the expression of genes in the apoptosis pathway in human bladder cancer cell line (T24). DNA and Cell Biology. 2014;33:408-17.

Zhang HY, Zhang PN, Sun H. Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy. European Journal of Obstetrics, Gynecology, and Reproductive Biology. 2009;146:81-6.

Gagnon V, Mathieu I, Sexton E, et al. AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecological Oncology. 2004;94:785-95.

Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes & development. 1999;13:1501-12.

Zhang P, Zhang Z, Zhou X, et al. Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line. BMC Cancer. 2006;6:224.

Zhu H, Wu J, Zhang W, et al. PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer. Scientific Reports. 2016;6:30788.

Ji J, Zheng PS. Activation of mTOR signaling pathway contributes to survival of cervical cancer cells. Gynecological Oncology. 2010;117:103-8.

Sims JT, Ganguly S, Fiore LS, et al. STI571 sensitizes breast cancer cells to 5-fluorouracil, cisplatin and camptothecin in a cell type-specific manner. Biochemical Pharmacology. 2009;78:249-60

Liu T, Peng H, Zhang M, et al. Cucurbitacin B, a small molecule inhibitor of the Stat3 signaling pathway, enhances the chemosensitivity of laryngeal squamous cell carcinoma cells to cisplatin. European Journal of Pharmacology. 2010;641:15-22.

Published
2019-12-21
Section
Original Research